Zepbound

News

Eli Lilly is predicting strong sales and profit growth in 2026, seemingly shrugging off the pricing pressure that weighed heavily on Novo Nordisk.

News

Lilly breaks new ground for oral GLP-1 agonists with data showing it can help patients keep weight off after treatment with injectable therapies.

News

Eli Lilly has enlisted the aid of Tan France of US makeover show Queer Eye to change the narrative about obesity in a new campaign.

News

The pricing agreement between Novo Nordisk and Eli Lilly and the Trump administration on GLP-1 drugs for diabetes and obesity has arrived.

News

Eli Lilly is celebrating a massive 54% increase in its third-quarter revenues to $17.6 billion, driven by its medicines for diabetes and obesity.

News

European doctors have said GLP-1 drugs are so effective in obesity that they should be the first choice drug treatment in almost all cases.